EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Tolerability of hormonal treatments in acute hepatic porphyria patients

Andjela Arandjelovic iD, Charlotte Ross, Gayle Ross iD

Internal Medicine Journal · 2026

DOI: 10.1111/imj.70532 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Internal Medicine Journal, 2026. Verfasst von Andjela Arandjelovic und 2 weiteren Autor:innen. Beteiligte Einrichtung: Porphyria Expert Centre, The Royal Melbourne Hospital, Parkville, Victoria, Australia. Hauptthemen laut MEDLINE: Porphyrias, Hepatic, Hormone Replacement Therapy. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Acute hepatic porphyria (AHP) flares have been associated with female hormones and the use of hormonal treatments. Women with AHP are traditionally advised to avoid exogenous oestrogen and progesterone, limiting options for contraception and management of menorrhagia, dysmenorrhoea and menopausal symptoms. Evidence on specific hormonal therapies is limited; a 2003 study found that 25% of women with acute intermittent porphyria (AIP) experienced attacks with contraceptives containing progesterone, oestrogen or both.

Aim

To update the current understanding of the tolerability of hormonal treatments in women with AHP.

Methods

An anonymous questionnaire was distributed to women with AHP (acute intermittent porphyria, hereditary coproporphyria and variegate porphyria) via hospital records and a national patient support group, capturing prior hormonal therapy use and associated flares.

Results

Thirty responses were analysed; 23 participants had used hormonal therapies. Flares were most frequent in hereditary coproporphyria (66%) and less common in variegate porphyria and acute intermittent porphyria (~20%). No flares were reported with hormone replacement therapy, the progesterone‐only pill or progesterone implants. Flares occurred with combined oral contraceptives (46.6%) and progesterone‐containing intrauterine devices (28.5%), particularly drospirenone‐containing pills. Levonorgestrel‐based therapies, including the Mirena IUD, were better tolerated and often improved symptoms.

Conclusions

Although limited by sample size and retrospective design, this study provides clinically useful data on the tolerability of specific hormonal therapies in women with AHP, supporting personalised prescribing and patient counselling for contraception and symptom management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Porphyrias, HepaticHormone Replacement TherapyHumansFemaleAdultProgesteroneMiddle AgedSurveys and QuestionnairesEstrogensPorphyria, Acute IntermittentEstrogen Replacement TherapyPorphobilinogen Synthase

Stichwörter der Autor:innen

acute hepatic porphyriaacute intermittent porphyriahereditary coproporphyriahormonal treatmentvariegate porphyria

Substanzen

ProgesteroneEstrogensPorphobilinogen Synthase

Autor:innen und Institutionen

  • Porphyria Expert Centre, The Royal Melbourne Hospital, Parkville, Victoria, Australia.

ORCID-Profile: Andjela Arandjelovic, Gayle Ross

Zitieren

APA

Arandjelovic, A., Ross, C., & Ross, G. (2026). Tolerability of hormonal treatments in acute hepatic porphyria patients. Internal Medicine Journal. https://doi.org/10.1111/imj.70532

Vancouver

Arandjelovic A, Ross C, Ross G. Tolerability of hormonal treatments in acute hepatic porphyria patients. Internal Medicine Journal. 2026. doi:10.1111/imj.70532

BibTeX
@article{Arandjelovic2026,
  author = {Arandjelovic, Andjela and Ross, Charlotte and Ross, Gayle},
  title = {Tolerability of hormonal treatments in acute hepatic porphyria patients},
  journal = {Internal Medicine Journal},
  year = {2026},
  doi = {10.1111/imj.70532}
}
Kostenlos starten →